# Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin

> **NCT03426033** · PHASE1 · COMPLETED · sponsor: **Akcea Therapeutics** · enrollment: 18 (actual)

## Conditions studied

- Elevated Lipoprotein(a)
- Cardiovascular Diseases

## Interventions

- **DRUG:** ISIS 681257
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT03426033
- **Lead sponsor:** Akcea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-15
- **Primary completion:** 2018-02-25
- **Final completion:** 2018-02-25
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2018-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03426033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03426033, "Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03426033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*